

# STATE OF NEW YORK

7979

2017-2018 Regular Sessions

## IN ASSEMBLY

May 23, 2017

Introduced by M. of A. QUART -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to prohibiting certain insurance policies from requiring prior authorization for certain medications used in the treatment of substance use disorders; and to repeal certain provisions of such law relating thereto

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Paragraph 31-a of subsection (i) of section 3216 of the  
2 insurance law is REPEALED and a new paragraph 31-a is added to read as  
3 follows:

4 (31-a) (A) No policy that provides medical, major medical or similar  
5 comprehensive-type coverage and provides coverage for prescription drugs  
6 for medication for the treatment of a substance use disorder shall  
7 require prior authorization for an initial or renewal prescription for  
8 all buprenorphine products or long acting injectable naltrexone for  
9 detoxification or maintenance treatment of a substance use disorder  
10 except where otherwise prohibited by law.

11 (B) Coverage provided under this paragraph may be subject to copay-  
12 ments, coinsurance, and annual deductibles that are consistent with  
13 those imposed on other benefits within the policy.

14 § 2. Paragraphs 7-a and 7-b of subsection (l) of section 3221 of the  
15 insurance law are REPEALED and a new paragraph 7-a is added to read as  
16 follows:

17 (7-a) (A) Every policy that provides medical, major medical or similar  
18 comprehensive-type large group coverage shall provide immediate coverage  
19 for all buprenorphine products or long acting injectable naltrexone  
20 without prior authorization for the detoxification or maintenance treat-  
21 ment of a substance use disorder.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD11793-01-7

1 (B) Coverage provided under this paragraph may be subject to copay-  
2 ments, coinsurance, and annual deductibles that are consistent with  
3 those imposed on other benefits within the policy.

4 § 3. Subsections (1-1) and (1-2) of section 4303 of the insurance law  
5 are REPEALED and a new subsection (1-1) is added to read as follows:

6 (1-1) (A) Every contract that provides medical, major medical, or  
7 similar comprehensive-type large group coverage shall provide immediate  
8 coverage for all buprenorphine products or long acting injectable  
9 naltrexone without prior authorization for the detoxification or mainte-  
10 nance treatment of a substance use disorder.

11 (B) Coverage provided under this paragraph may be subject to copay-  
12 ments, coinsurance, and annual deductibles that are consistent with  
13 those imposed on other benefits within the policy.

14 § 4. This act shall take effect on the sixtieth day after it shall  
15 have become a law.